Advisor Group’s Atara Biotherapeutics ATRA Stock Holding History

Advisor Group’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$5K	Sell	12 -8	-40%	-$2.76K	﹤0.01%	4640
2019 Q3	$7K	Buy	20 +2	+11%	+$746	﹤0.01%	4494
2019 Q2	$9K	Sell	18 -1	-5%	-$706	﹤0.01%	4413
2019 Q1	$19K	Buy	19 +4	+27%	+$3.72K	﹤0.01%	4001
2018 Q4	$13K	Hold	15	–	–	﹤0.01%	4053
2018 Q3	$16K	Hold	15	–	–	﹤0.01%	4014
2018 Q2	$14K	Sell	15 -1	-6%	-$1.07K	﹤0.01%	3898
2018 Q1	$15K	Hold	16	–	–	﹤0.01%	3842
2017 Q4	$8K	Buy	16 +6	+60%	+$2.22K	﹤0.01%	4196
2017 Q3	$4K	Buy	10 +5	+100%	+$1.89K	﹤0.01%	4334
2017 Q2	$1K	Sell	5 -1	-17%	-$385	﹤0.01%	4604
2017 Q1	$4K	Hold	6	–	–	﹤0.01%	4181
2016 Q4	$1K	Buy	6 +2	+50%	+$847	﹤0.01%	4329
2016 Q3	$2K	Buy	4 +1	+33%	+$543	﹤0.01%	4140
2016 Q2	$1K	Buy	+3	New	+$1.44K	﹤0.01%	4198

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Advisor Group's ATRA Position: Q4 2019 in Review

Advisor Group reduced its Atara Biotherapeutics (ATRA) stake by 40% in Q4 2019, selling an estimated $2.76K and leaving 12 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4640.

Advisor Group first reported a position in ATRA in Q2 2016 and has held it in 15 quarters since. The position peaked at $19K in Q1 2019. 117 funds tracked by Wall St. Rank hold ATRA as of Q4 2019.

Advisor Group held 12 shares of Atara Biotherapeutics worth $5K as of Q4 2019.
Advisor Group sold 8 Atara Biotherapeutics shares in Q4 2019, an estimated $2.76K.
Atara Biotherapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4640 holding.
Advisor Group first reported a position in Atara Biotherapeutics in Q2 2016 and has held it in 15 quarters since.
Advisor Group's Atara Biotherapeutics position peaked at $19K in Q1 2019.
117 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.